Health products policy and standards
Our team provides authoritative guidance and standards on quality, safety and efficacy of health products and supports countries to formulate evidence-based policies and ensure good practice throughout the value chain.
Working documents in public consultation
Please provide any comments you may have as per the instructions indicated in the text box on the first page of each working document. Comments should be submitted through the PleaseReviewTM online platform which facilitates document review, co-authoring and redaction. To register on this PleaseReview platform, please contact nsp@who.int. You may use the Table for comments template if you are unable to access the PleaseReview platform.
- WHO listing of quality control laboratories: procedure for assessing the acceptability, in principle, of quality control laboratories for use by United Nations agencies (QAS/25.979)
- Regulatory considerations for the life cycle of medical oxygen (QAS/25.978)
- World Health Organization/United Nations Population Fund specifications for plain lubricants (QAS/25.977)
- International Atomic Energy Agency (IAEA)/WHO guidelines on good practices for quality control of radiopharmaceutical products (QAS24.969)
- Procedure for prequalification of pharmaceutical products (QAS/25.974)
- WHO General guidelines for the establishment, maintenance and distribution of chemical reference substances (QAS/25.972)
- Ethambutol Dihydrochloride tablets (Ethambutoli Dihydrochloridi compressi) (QAS/24.960)
- WHO Points to consider in continuous manufacturing of pharmaceutical products (QAS/24.957)
- Development of paediatric medicines: points to consider in formulation (QAS/24.950)
- Aminosalicylate Sodium delayed-release tablets (Aminosalicylati Natrii compressi ad tardatam liberationem) (QAS/20.845)
- Aminosalicylate Sodium Dihydrate (Aminosalicylatum Natricum Dihydricus) (QAS/20.844)
New working documents under review for norms and standards for pharmaceuticals
Monographs and general texts under review/revision for inclusion in The International Pharmacopoeia
for inclusion in the International Pharmacopoeia
- DIETHYLCARBAMAZINE DIHYDROGEN CITRATE (QAS/21.896)
- MEDICINAL OXYGEN (QAS/24.949)
- ETHAMBUTOL DIHYDROCHLORIDE DISPERIBLE TABLETS (QAS/23.935)
- ZIDOVUDINE (QAS/22.918)
- DARUNAVIR TABLETS (DARUNAVIRI COMPRESSI) (QAS/20.830)
- DARUNAVIR ORAL SUSPENSION (DARUNAVIRI SUSPENSIO PERORALUM) (QAS/20.848)
- DARUNAVIR (DARUNAVIRUM) (QAS/20.829)
- CAPSULES (QAS/23.927)
- ZIDOVUDINE (ZIDOVUDINUM) (QAS/22.918)
- ZIDOVUDINE CAPSULES (ZIDOVUDINI CAPSULAE) (QAS/22.933)
- MIFEPRISTONE TABLETS (MIFEPRISTONI COMPRESSI) (QAS/24.959)
- MIFEPRISTONE (MIFEPRISTONUM) (QAS/24.958)
- CLOFAZIMINE (CLOFAZIMINUM) (QAS/24.954)